SAB Biotherapeutics Inc. (SABS)
$3.72
$-0.03
(-0.80%)
As on 03-Sep-2026 16:00EDT
Market cap
$345 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
15.8
P/B Ratio
1.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
64.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.4
-
Face value
--
-
Shares outstanding
90,986,368
5 Years Aggregate
CFO
$-16.81 Mln
EBITDA
$-60.30 Mln
Net Profit
$-67.68 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
SAB Biotherapeutics (SABS)
| -0.5 | 4.2 | 6.9 | 75.5 | -20.2 | -48.2 | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
SAB Biotherapeutics (SABS)
| -1.4 | -44.6 | 16.6 | -92.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
SAB Biotherapeutics (SABS)
|
3.7 | 344.8 | 0.0 | -12.8 | -- | -7 | 15.8 | 1.7 |
| 86.5 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 74.0 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.1 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.8 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 371.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 542.6 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 593.4 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 355.2 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 148.8 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout SAB Biotherapeutics (SABS)
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product... candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida. Read more
-
CEO & Executive Chairman
Mr. Samuel J. Reich
-
CEO & Executive Chairman
Mr. Samuel J. Reich
-
Headquarters
Miami Beach, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for SAB Biotherapeutics (SABS)
What is the current share price of SAB Biotherapeutics Inc (SABS) Today?
The share price of SAB Biotherapeutics Inc (SABS) is $3.72 (NASDAQ) as of 03-Sep-2026 16:00 EDT. SAB Biotherapeutics Inc (SABS) has given a return of -20.25% in the last 3 years.
What is the current PB & PE ratio of SAB Biotherapeutics Inc (SABS)?
The P/E ratio of SAB Biotherapeutics Inc (SABS) is 15.79 times as on 28-Aug-2026.
The P/B ratio of SAB Biotherapeutics Inc (SABS) is 1.66 times as on 28-Aug-2026, a 68 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
13.41 |
1.18 |
2024 |
-1.03 |
1.35 |
2023 |
-0.10 |
0.07 |
2022 |
-1.59 |
0.96 |
2021 |
-1.98 |
0.88 |
What is the 52 Week High and Low of SAB Biotherapeutics Inc (SABS)?
The 52-week high and low of SAB Biotherapeutics Inc (SABS) are Rs 5.15 and Rs 1.85 as of 04-Sep-2026.
What is the market cap of SAB Biotherapeutics Inc (SABS)?
SAB Biotherapeutics Inc (SABS) has a market capitalisation of $ 345 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in SAB Biotherapeutics Inc (SABS)?
Before investing in SAB Biotherapeutics Inc (SABS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.